European Patent granted for Intercell's synthetic adjuvant IC31TM
IC31TM is an adjuvant that induces Tcell and Bcell responses by using a unique synthetic formulation which combines the immunostimulating properties of an antimicrobial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens; no conjugation is required.
Intercell currently uses IC31(TM) in collaborations with a number of global vaccine companies and biotech companies. These collaborations include the development of a tuberculosis vaccine in Phase I clinical trials, which has been partnered with the Danish Statens Serum Institut, and the development of a therapeutic Hepatitis B vaccine with SciGen Ltd.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.